[go: up one dir, main page]

EA201201569A1 - Инъекционная композиция пролонгированного действия для введения антипсихотического препарата - Google Patents

Инъекционная композиция пролонгированного действия для введения антипсихотического препарата

Info

Publication number
EA201201569A1
EA201201569A1 EA201201569A EA201201569A EA201201569A1 EA 201201569 A1 EA201201569 A1 EA 201201569A1 EA 201201569 A EA201201569 A EA 201201569A EA 201201569 A EA201201569 A EA 201201569A EA 201201569 A1 EA201201569 A1 EA 201201569A1
Authority
EA
Eurasian Patent Office
Prior art keywords
drug
composition
introduction
prolonged action
antipsychotic drug
Prior art date
Application number
EA201201569A
Other languages
English (en)
Other versions
EA024155B1 (ru
Inventor
Ибон Гутьерро Адурис
Мария Тереса Гомес Очоа
Original Assignee
Лабораториос Фармасеутикос Рови, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43301889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201201569(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Лабораториос Фармасеутикос Рови, С.А. filed Critical Лабораториос Фармасеутикос Рови, С.А.
Publication of EA201201569A1 publication Critical patent/EA201201569A1/ru
Publication of EA024155B1 publication Critical patent/EA024155B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Изобретение представляет собой композиции для инъекционных, образующихся in situ биоразлагаемых имплантатов пролонгированного действия, служащих для доставки в организм антипсихотических препаратов, как рисперидон, и обеспечения его терапевтической концентрации в плазме крови с первого дня. Композиция представляет собой суспензию препарата, помещенную в биоразлагаемый и биосовместимый сополимер или сополимерный раствор, с использованием смешиваемого с водой раствора, которые вводятся в жидкой форме. Когда эта композиция подвергается воздействию биологических жидкостей, полимерная матрица затвердевает и удерживает препарат, образуя твердый или полутвердый имплантат, который освобождает препарат в постоянном режиме. Терапевтические концентрации препарата в плазме крови могут быть достигнуты с первого дня до по меньшей мере 14 дня или более.
EA201201569A 2010-05-31 2011-05-31 Инъекционная композиция пролонгированного действия для введения антипсихотического препарата EA024155B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382154.2A EP2394664B1 (en) 2010-05-31 2010-05-31 Antipsychotic injectable depot composition
PCT/EP2011/059000 WO2011151355A1 (en) 2010-05-31 2011-05-31 Antipsychotic injectable depot composition

Publications (2)

Publication Number Publication Date
EA201201569A1 true EA201201569A1 (ru) 2013-04-30
EA024155B1 EA024155B1 (ru) 2016-08-31

Family

ID=43301889

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201569A EA024155B1 (ru) 2010-05-31 2011-05-31 Инъекционная композиция пролонгированного действия для введения антипсихотического препарата

Country Status (33)

Country Link
US (2) US10085936B2 (ru)
EP (2) EP2394664B1 (ru)
JP (1) JP5882993B2 (ru)
KR (1) KR101784330B1 (ru)
CN (1) CN103002917B (ru)
AP (1) AP3524A (ru)
AU (1) AU2011260318B2 (ru)
BR (1) BR112012030686B1 (ru)
CA (1) CA2800111C (ru)
CL (1) CL2012003350A1 (ru)
CY (2) CY1117969T1 (ru)
DK (2) DK2394664T3 (ru)
EA (1) EA024155B1 (ru)
ES (2) ES2589106T3 (ru)
HR (2) HRP20161049T1 (ru)
HU (2) HUE029895T2 (ru)
IL (1) IL223129A (ru)
LT (2) LT2394664T (ru)
MA (1) MA34296B1 (ru)
ME (1) ME02501B (ru)
MX (1) MX338373B (ru)
MY (1) MY161930A (ru)
NZ (1) NZ604342A (ru)
PH (1) PH12012502338B1 (ru)
PL (2) PL2394664T3 (ru)
PT (2) PT2394664T (ru)
RS (1) RS55190B1 (ru)
SG (1) SG185775A1 (ru)
SI (2) SI2394664T1 (ru)
SM (2) SMT201600321B (ru)
UA (1) UA108885C2 (ru)
WO (1) WO2011151355A1 (ru)
ZA (1) ZA201209346B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2008153611A2 (en) 2007-05-25 2008-12-18 Qlt Usa, Inc. Sustained delivery formulations of risperidone compounds
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
LT2394663T (lt) 2010-05-31 2022-02-10 Laboratorios Farmaceuticos Rovi, S.A. Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
HUE029895T2 (en) 2010-05-31 2017-04-28 Farm Rovi Lab Sa Antipsychotic injectable depot composition
DK2529756T3 (da) * 2011-05-31 2021-08-02 Farm Rovi Lab Sa Risperidon- og/eller paliperidon-implantatformulering
PL2529757T3 (pl) * 2011-05-31 2014-04-30 Farm Rovi Lab Sa Formulacja implantu zawierającego paliperydon
AU2014249008B2 (en) 2013-03-11 2018-12-06 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
WO2016199170A2 (en) * 2015-06-10 2016-12-15 Cipla Limited Paliperidone palmitate particles and compositions thereof
JP2020511483A (ja) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
CN110420212A (zh) * 2019-08-19 2019-11-08 韩自勤 一种用于治疗精神分裂症组合物及其制备方法
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
AU2023281232A1 (en) 2022-05-18 2024-10-24 Laboratorios Farmacéuticos Rovi, S.A. Prolonged-release injectable compositions for use in treatment with risperidone together with cyp2d6 enzyme inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE758156R (fr) 1970-05-13 1971-04-28 Ethicon Inc Element de suture absorbable et sa
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4523591A (en) 1982-10-22 1985-06-18 Kaplan Donald S Polymers for injection molding of absorbable surgical devices
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5620700A (en) 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
SG47445A1 (en) 1993-11-19 1998-04-17 Janssen Pharmaceutica Nv Microencapsulated 3-piperidinyl-substituted1 1 2-benzisoxazoles and 1 2-benzisothiazoles
WO1998027962A2 (en) 1996-12-20 1998-07-02 Alza Corporation Injectable depot gel composition and method of preparing the composition
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6331317B1 (en) * 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
DK1248596T3 (da) * 2000-01-11 2007-07-02 Bertex Pharma Gmbh Implantater, partikler
US6604561B2 (en) * 2000-02-11 2003-08-12 Medical Instill Technologies, Inc. Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial
BR0313539A (pt) * 2002-07-31 2005-06-21 Alza Corp Composições depósito de polìmero multimodais injetáveis e seus usos
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US20050003007A1 (en) 2003-07-02 2005-01-06 Michele Boix Method of sterilization of polymeric microparticles
DK1660039T3 (en) * 2003-07-18 2017-01-16 Oakwood Laboratories L L C PREVENTION OF REDUCTION OF THE POLYMER MOLECULE WEIGHT, THE PREPARATION OF PURPOSES AND GELING IN POLYMER COMPOSITIONS
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
DE102005031868A1 (de) * 2005-07-04 2007-01-18 Biotronik Vi Patent Ag Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
FR2908775B1 (fr) * 2006-11-17 2012-08-31 Biomatlante Hydrogel et ses applications biomedicales
EP3202814B1 (en) 2007-02-15 2019-10-16 Tolmar Therapeutics, Inc. Low burst poly-(lactide/glycolide) and methods to produce polymers
HUE030789T2 (en) * 2007-05-18 2017-06-28 Durect Corp Improved depot formulation
WO2008153611A2 (en) * 2007-05-25 2008-12-18 Qlt Usa, Inc. Sustained delivery formulations of risperidone compounds
AR070033A1 (es) * 2007-11-06 2010-03-10 Panacea Biotec Ltd Composiciones inyectables, sus procesos y usos
PL2323623T3 (pl) * 2008-08-12 2017-04-28 Novartis Ag Kompozycje farmaceutyczne
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
LT2394663T (lt) 2010-05-31 2022-02-10 Laboratorios Farmaceuticos Rovi, S.A. Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams
HUE029895T2 (en) 2010-05-31 2017-04-28 Farm Rovi Lab Sa Antipsychotic injectable depot composition
DK2529756T3 (da) 2011-05-31 2021-08-02 Farm Rovi Lab Sa Risperidon- og/eller paliperidon-implantatformulering
PL2529757T3 (pl) 2011-05-31 2014-04-30 Farm Rovi Lab Sa Formulacja implantu zawierającego paliperydon

Also Published As

Publication number Publication date
HRP20161049T1 (hr) 2016-12-30
SMT201600321B (it) 2016-11-10
EP2394664B1 (en) 2016-06-01
US20180221272A1 (en) 2018-08-09
MX2012013937A (es) 2013-02-11
CN103002917B (zh) 2016-04-27
HRP20161100T1 (hr) 2016-11-04
IL223129A0 (en) 2013-02-03
MA34296B1 (fr) 2013-06-01
SG185775A1 (en) 2013-01-30
DK2394664T3 (en) 2016-09-12
AP2012006626A0 (en) 2012-12-31
US10085936B2 (en) 2018-10-02
PT2394664T (pt) 2016-09-06
RS55190B1 (sr) 2017-01-31
ES2592527T3 (es) 2016-11-30
CL2012003350A1 (es) 2013-10-18
MY161930A (en) 2017-05-15
DK2575890T3 (en) 2016-09-12
NZ604342A (en) 2014-11-28
CA2800111A1 (en) 2011-12-08
AU2011260318B2 (en) 2014-11-27
EP2575890A1 (en) 2013-04-10
PH12012502338B1 (en) 2018-08-31
CY1117964T1 (el) 2017-05-17
EP2394664A1 (en) 2011-12-14
KR20130118742A (ko) 2013-10-30
MX338373B (es) 2016-04-13
US20130171202A1 (en) 2013-07-04
SI2394664T1 (sl) 2016-10-28
KR101784330B1 (ko) 2017-10-11
EA024155B1 (ru) 2016-08-31
US10182982B2 (en) 2019-01-22
BR112012030686A2 (pt) 2020-08-25
ES2589106T3 (es) 2016-11-10
PT2575890T (pt) 2016-09-06
CA2800111C (en) 2018-05-22
AP3524A (en) 2016-01-11
PL2394664T3 (pl) 2016-12-30
BR112012030686B1 (pt) 2022-11-01
EP2575890B1 (en) 2016-06-01
CN103002917A (zh) 2013-03-27
ZA201209346B (en) 2013-08-28
LT2394664T (lt) 2016-09-26
HUE029895T2 (en) 2017-04-28
IL223129A (en) 2016-02-29
ME02501B (me) 2017-02-20
PL2575890T3 (pl) 2016-12-30
SMT201600320B (it) 2016-11-10
JP5882993B2 (ja) 2016-03-09
HUE029056T2 (en) 2017-02-28
SI2575890T1 (sl) 2016-10-28
AU2011260318A1 (en) 2013-01-10
UA108885C2 (uk) 2015-06-25
LT2575890T (lt) 2016-09-26
PH12012502338A1 (en) 2013-02-11
WO2011151355A1 (en) 2011-12-08
JP2013528612A (ja) 2013-07-11
CY1117969T1 (el) 2017-05-17

Similar Documents

Publication Publication Date Title
EA201201569A1 (ru) Инъекционная композиция пролонгированного действия для введения антипсихотического препарата
Sharma et al. An insight into functionalized calcium based inorganic nanomaterials in biomedicine: Trends and transitions
EA201190300A1 (ru) Микроэлектрод и множественные микроэлектроды, содержащие устройства для высвобождения лекарственных средств в ткани
MY167123A (en) Conveniently implantable sustained release drug compositions
BRPI0822625B8 (pt) dispositivo espaçador modular para o tratamento de infecções por próteses
WO2010039641A3 (en) Long term drug delivery devices with polyurethane-based polymers and their manufacture
EA201000897A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
MY155961A (en) Chemical compounds 251
EP2349367A4 (en) MODIFIED SILK FILMS WITH GLYCEROL
IN2013MN00758A (ru)
AU2012340752A8 (en) Implantable solid-liquid drug delivery apparatus, formulations, and methods of use
HRP20211853T1 (hr) Sastavi in situ injekcijskih biorazgradivih implantata
MX2009006447A (es) Composicion farmaceutica de liberacion sostenida a largo plazo que contiene suspension acuosa de bisfosfonato.
MX2009011316A (es) Derivados del acido lipoico.
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
ATE485832T1 (de) Glucoseisomerase zur behandlung von fructose- unverträglichkeit
MX351282B (es) Stent de metal sin recubrir con depósitos de elución de fármaco que tiene retención de fármaco mejorada.
NZ591496A (en) A medicinal comprising ibuprofen and paracetamol and treatment for arthritis
WO2011089618A3 (en) Drug-eluting insert able medical device for treating acute myocardial infarction, thrombus containing lesions and saphenous- vein graft lesions
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
BRPI0519022A2 (pt) formaÇço insitu de implante para animais
UA103635C2 (ru) Имплантированное устройство для введения рисперидона и способ его использования
EA200701591A1 (ru) Композиции с контролируемым высвобождением, содержащие антипсихотическое средство
WO2009038106A1 (ja) アラニルチロシンを含有する経口剤